Kenneth Yu
Associate Attending Physician · New York Presbyterian Hospital
Credentials: · · · · ·
History
Research
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
Nature · 2011 · 1,881 citations
Cancer Discovery · 2019 · 1,796 citations
Organoid models of human and mouse ductal pancreatic cancer
Cell · 2015 · 1,755 citations
- EO
67 papers
- AV
35 papers
- DK
27 papers
- ML
26 papers · 12 as a resident
- WP
26 papers
- CI
19 papers
- ZS
15 papers · 1 as a fellow
- GA
13 papers
Grants
- 2017–2023
Protein and Proteolytic Activity Biomarkers of Early Stage Pancreatic Cancer
National Cancer Institute · R01
PI · $3.1M · Sloan-Kettering Inst Can Research
- 2016–2022
Imaging Drug Uptake and Distribution in Chemoradiation Therapy of Pancreatic Cancer
National Cancer Institute · R01
PI · $2M · Sloan-Kettering Inst Can Research
- 2016–2021
Pharmacogenomic and Circulating Tumor Cell Approach to Individualized Treatment of Pancreatic Cancer
National Cancer Institute · R01
Contact PI · $2.8M · Sloan-Kettering Inst Can Research
- 2011–2014
Biomarkers of Exposure and Response to Environmental Tobacco Smoke in the Pancrea
National Institute of Environmental Health Sciences · K08
Contact PI · $541.1K · Sloan-Kettering Inst Can Research
Clinical trials
- 2019–2027
A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer
Principal investigator · Active not recruiting · Phase 1
Memorial Sloan Kettering Cancer Center
- 2016–2026
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Principal investigator · Active not recruiting
Memorial Sloan Kettering Cancer Center
- 2014–2016
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
- 2011–2019
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center